alcohol brands

335 registered brands containing alcohol in Tanzania.

Alcohol 2D chemical structure

2D structure

Alcohol

PubChem CID 702

Molecular formula: C2H6O

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Source: PubChem (NCBI) · compound 702

Product Manufacturer Status Country
PANGRAF 5
Capsules
Panacea Biotec Registered/Compliant Tanzania
Pantocar-40
Tablets
Micro Labs Registered/Compliant Tanzania
PANTOTAB
Tablets
Micro Labs Registered/Compliant Tanzania
PET D WORM TABLETS
Tablets
Medisel Registered/Compliant Tanzania
PHENOKEM 500
Tablet
Alkem Laboratories Limited Registered/Compliant Tanzania
Phenoxymethylpenicillin
Tablets
Medopharm Registered/Compliant Tanzania
PIXAB 2.5
Tablets
Pinnacle Life Science Registered/Compliant Tanzania
PIXAB 5
Tablets
Pinnacle Life Science Registered/Compliant Tanzania
Planilon
Solution
Sri Balaji Pharma Registered/Compliant Tanzania
Prazitel
Tablets
Cosmos Registered/Compliant Tanzania
Pricostat V Cream
Vaginal Cream
Prince Pharmaceuticals Registered/Compliant Tanzania
QPOL-ANTISEPTIC LIQUID
Liquid
Sterling Surfactants Registered/Compliant Tanzania
Quanil Granules 500 mg
Granules for Oral solution
Kusum Healthcare Registered/Compliant Tanzania
QUITIDE 200
Film Coated Tablet
Aurobindo Pharma Registered/Compliant Tanzania
QUITIDE 300
Film coated tablets
Aurobindo Pharma Registered/Compliant Tanzania
Rabemac 20
Tablet, Enteric Coated
Macleods Pharmaceuticals Registered/Compliant Tanzania
REGESTEN
Cream
Bal Pharma Registered/Compliant Tanzania
RELAXO
Gel
Lincoln Pharmaceuticals Registered/Compliant Tanzania
Relaxo Gel
Gel
Lincoln Pharmaceuticals Limited Registered/Compliant Tanzania
REZOL-20
Tablet, Enteric Coated
Resonant Pharmaceuticals Registered/Compliant Tanzania
Rifampin, Isoniazid and Pyrazinamide Dispersible Tablets
Dispersible Tablets
Lupin Registered/Compliant Tanzania
Rimonid Eye Drops
Ophthalmic Solution
Micro Labs Registered/Compliant Tanzania
Rivamac 10
Film Coated Tablet
Macleods Pharmaceuticals Registered/Compliant Tanzania
Rivamac 15 (Rivaroxaban film coated Tablets 15 mg)
Film Coated Tablet
Macleods Pharmaceuticals Registered/Compliant Tanzania
Rivamac 20
Film Coated Tablet
Macleods Pharmaceuticals Registered/Compliant Tanzania
S-QUIN
Solution for injection
Swiss Parenterals Registered/Compliant Tanzania
SACUVAN 24/ 26
Tablets
Hetero Laboratories Registered/Compliant Tanzania
SACUVAN 49/51
Tablets
Hetero Laboratories Registered/Compliant Tanzania
SACUVAN 97/103
Tablets
Hetero Laboratories Registered/Compliant Tanzania
Sacuzac 100
Oral tablet
Ajanta Pharma Registered/Compliant Tanzania
Sacuzac 200
Oral tablet
Ajanta Pharma Registered/Compliant Tanzania
septol hand sanitizer
Gel
Mamujee Products Registered/Compliant Tanzania
Sevlon
Liquid
Cure Afya Registered/Compliant Tanzania
SILVERINE
Cream
Bal Pharma Registered/Compliant Tanzania
Sitamac 100
Film Coated Tablet
Macleods Pharmaceuticals Registered/Compliant Tanzania
Sitamac 50
Film Coated Tablet
Macleods Pharmaceuticals Registered/Compliant Tanzania
SKLOBETA
Cream
S Kant Healthcare Registered/Compliant Tanzania
Solvent for Docetaxel Injection
Injection
Cisen Pharmaceutical Co., Ltd Registered/Compliant Tanzania
Sompraz 40
Tablets
Sun Pharmaceuticals Registered/Compliant Tanzania
SPINO-25
Film Coated Tablet
Resonant Pharmaceuticals Registered/Compliant Tanzania
STERLING INSTANT HAND SANITIZER
Liquid
Sterling Surfactants Registered/Compliant Tanzania
Strepsils Honey and Lemon
Lozenges
Reckitt Benckiser Registered/Compliant Tanzania
Strepsils Original Lozenges
Lozenges
Reckitt Benckiser Registered/Compliant Tanzania
SUDIF CREAM
Cream
Klm Laboratories Pvt. Ltd Registered/Compliant Tanzania
SUVITRA-750
Tablets
Micro Labs Registered/Compliant Tanzania
TAGRISSO 40mg
Film Coated Tablet
AstraZeneca Registered/Compliant Tanzania
TAGRISSO 80mg
Film Coated Tablet
AstraZeneca Registered/Compliant Tanzania
TAXELDO 80
Injection
Hetero Labs Registered/Compliant Tanzania
TERBICOR CREAM
Cream
Coral Laboratories Registered/Compliant Tanzania
TERBOKANT
Cream
S Kant Healthcare Registered/Compliant Tanzania
4567